ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1896

No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis

Mary Lucy Marques1, Sofia Ramiro2, Pedro M Machado3, Désirée van der Heijde4 and Floris van Gaalen5, 1Leiden University Medical Center, Coimbra, Portugal, 2Leiden University Medical Center, Bunde, Netherlands, 3University College London, London, United Kingdom, 4Leiden University Medical Center, Leiden, Netherlands, 5Leiden University Medical Center (LUMC), Leiden, Netherlands

Meeting: ACR Convergence 2020

Keywords: Bone density, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA) it has been hypothesized that inflammation-driven bone loss triggers bone repair but at anatomically distinct sites of the same vertebra (i.e. bone loss occurring in the trabecular bone and bone repair in the periosteum)1. However, the possible association between bone loss and new bone formation at the same individual vertebra has never been studied. The purpose of this study was to investigate if in r-axSpA low vertebral bone mineral density (BMD) is associated with development of new syndesmophytes at the same vertebral level.

Methods: In a post-hoc analysis from the ASSERT trial (infliximab vs placebo) dual-energy X-ray absorptiometry was used to measure baseline BMD (g/cm2) of the lumbar spine L1 to L4. Syndesmophyte formation was assessed in the same vertebrae on conventional radiographs defined as an increase in modified Stoke Ankylosing Spondylitis Spine Score from 0 or 1 to 2 or 3 after 2 years. Radiographs were scored by two readers. Generalized estimating equations (GEE) adjusted for within-patient correlation across multiple vertebrae, taking potential confounders into account (Table 1).

Results: We analyzed 599 vertebrae in 165 r-axSpA patients (78% male, mean (SD) age 38 (10) years, 67% with at least one syndesmophyte anywhere in the spine). In total, 24 to 74 new syndesmophytes developed in 9 (5%) to 30 (18%) patients and 13 (2%) to 39 (7%) vertebrae, if either a syndesmophyte was seen by both or only one of the readers (i.e. specific and sensitive definitions) respectively. Analyses with both definitions, and both uni- and multivariable, showed no significant association between baseline local vertebral BMD and new syndesmophyte formation after two years in the same vertebra (multivariable analysis adjOR (95%CI): 0.56 (0.01, 44.45) (specific definition) and 0.26 (0.03, 2.63) (sensitive definition)) (Table 1).

Conclusion: In patients with active and established r-axSpA, with an observed low incidence of lumbar spine syndesmophyte formation over two years, no relationship was found between baseline BMD and new radiographic syndesmophyte formation in the same vertebra.

1 Lories RJ. Best Pract Res Clin Rheumatol. 2018 Jun;32(3):331–41.

This study, carried out under YODA Project #2018-2761, used data obtained from the Yale University Open Data Access Project, which has an agreement with JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. The interpretation and reporting of research using this data are solely the responsibility of the authors and does not necessarily represent the official views of the Yale University Open Data Access Project or JANSSEN RESEARCH & DEVELOPMENT, L.L.C..


Disclosure: M. Marques, None; S. Ramiro, Abbvie, 8, Eli Lilly, 8, Novartis, 8, MSD, 8, UCB, 8, Sanofi, 8; P. Machado, Abbvie, 5, 8, Eli Lilly, 5, Novartis, 5, 8, UCB, 5, 8, Pfizer, 8; D. van der Heijde, AbbVie, 5, Bristol-Myers Squibb, 5, Cyxone, 5, Galapagos NV, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, UCB Pharma, 5, Amgen Inc., 5, Astellas, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, Daiichi-Sankyo, 5, Janssen, 5, Merck, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, Imaging Rheumatology bv, 3, Eisai, 5; F. van Gaalen, Reuma Nederland, 1, Stichting vrienden van Sole Mio, 1, MSD, 1, Abbvie, 1, Novartis, 1.

To cite this abstract in AMA style:

Marques M, Ramiro S, Machado P, van der Heijde D, van Gaalen F. No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/no-relationship-between-lumbar-bone-mineral-density-and-syndesmophyte-formation-at-the-same-level-a-multilevel-analysis-in-patients-with-radiographic-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-relationship-between-lumbar-bone-mineral-density-and-syndesmophyte-formation-at-the-same-level-a-multilevel-analysis-in-patients-with-radiographic-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology